7:57 PM GE - General Electric Healthcare and Thomson Reuters' Powerful Clinical Research Dataset | |
|
Research Data Repository is Combining Millions of De-identified Health Claim and Electronic Medical Records to Measure Efficacy of Drugs and Other Treatments Barrington, Illinois and New York - May 25, 2011-Pharmaceutical companies and other health organizations will now be able to do the research evidence based on data that allows them to better measure the effectiveness of medical treatment in discrete patient populations, thanks to new data and analytical solutions are developed and delivered by GE Healthcare and Thomson Reuters. If it is necessary to respond to appropriate health economics and population-based research questions, analysis of the health team at General Electric (NYSE: GE) and Thomson Reuters (NYSE: TRI) now has the ability to incorporate commonly used research data from Thomson Reuters MarketScan Research ® Database with de-identified electronic medical records, while maintaining patient privacy and in accordance with HIPAA standards .. As a result, researchers and doctors are now able to obtain new evidence-based insights into the treatment protocol. These insights can help drive improved health outcome. The addition of de-identified clinical data provided by health care providers use the EMR is a research study to evaluate medical care -. "Comparative effectiveness research" so-called "research" or the addition of de-identified clinical data from EMR that means research can link de-identified claims data from a population of patients diagnosed with certain conditions such as hypertension, with de-identified clinical data about everything from the patient's body mass index, blood pressure, symptoms and much more. This study will provide more specific evidence to allow doctors and patients to make better decisions. "We've handled what was once considered a barrier to overcome on the results of research-based," said Dr. Brandon Savage, MD, Chief Medical Officer at GE Healthcare IT. "We are very enthusiastic about the opportunities this invention to create jobs and overhauling a day may bring to the care of patients, all over the world." Researchers from GE Healthcare and Thomson Reuters' first show this approach to link de-identified data in a presentation at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held in Atlanta in May 2010. ISPOR Presentation, which used hypertension as a set of samples, combined de-identified clinical data collected from more than 9,000 electronic medical records with MarketScan claims and prescription data from more than 30 million people. Each dataset has grown enough so that the stronger the data source. Teams from both organizations have developed an algorithm that allows the de-identification of patient data without loss of utility. These companies then prove the ability to use the methodology to connect the region's additional therapy. They have now entered into a partnership to provide research and analytical service which is based on ability is proven. "We now can conduct studies that assess the effectiveness of medical treatment, prescription compliance, and disease management initiatives based on two sets of clinical data in-depth and extensive data on the full health experience of patients with de-identified. This includes all inpatient and outpatient visits and all prescriptions filled, cost, and reimbursement, "said Bill Marder, senior vice president at Thomson Reuters. The companies now attract customers and plan research that will demonstrate the value of this unique and comprehensive capabilities. For more information, please e-mail or cds@ge.com marketscan@thomsonreuters.com. | |
|
| |
| Total comments: 0 | |